Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 2837.

DOI: https://doi.org/10.1182/blood-2021-147188

Published: 2021

Journal Articles

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

Blood (2021) 138 (Supplement 1): 735.

DOI: https://doi.org/10.1182/blood-2021-148578

Published: 2021

Journal Articles

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Blood (2021) 138 (Supplement 1): 552.

DOI: https://doi.org/10.1182/blood-2021-148281

Published: 2021

Journal Articles

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, Monica Lopez-Guerra, Aina Oliver-Caldes, Anthony M Battram, Luis Gerardo Rodríguez-Lobato, Natalia Tovar, M. Teresa Cibeira, Raquel Jiménez-Segura, Joan Bladé Creixenti, Laura Rosinol, Dolors Colomer, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 462.

DOI: https://doi.org/10.1182/blood-2021-147168

Published: 2021

Journal Articles

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 480.

DOI: https://doi.org/10.1182/blood-2021-147774

Published: 2021

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

DOI: https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

Ignacio Isola, MD, David Moreno, MD, Esther Moga, MD PhD, Mari-Pau Mena, PhD, Natalia Tovar, Luis Gerardo Rodríguez-Lobato, MD PhD, M. Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Carlos Fernandez de Larrea, MD PhD

Blood (2020) 136 (Supplement 1): 2–3.

DOI: https://doi.org/10.1182/blood-2020-139737

Published: 2020

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

DOI: https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma

Carlos Fernandez de Larrea, MD PhD, Mette Staehr, PhD, Andrea Lopez, Yunxin Chen, MBBS, Terence J Purdon, MS, Khong Y. Ng, PhD, Hans Wendel, MD, Renier J. Brentjens, MD PhD, Eric L Smith, MD PhD

Blood (2019) 134 (Supplement_1): 136.

DOI: https://doi.org/10.1182/blood-2019-126145

Published: 2019

Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Blood (2018) 132 (Supplement 1): 1682.

DOI: https://doi.org/10.1182/blood-2018-99-117089

Published: 2018

Journal Articles

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Carlos Fernandez de Larrea, MD PhD, Ignacio Isola, MD, Esther Moga, Maria Teresa Cibeira, MD PhD, Ester Lozano, PhD, Juan I. Arostegui, Montserrat Elena, Natalia Tovar, MD PhD, Jordi Yague, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 4514.

DOI: https://doi.org/10.1182/blood-2018-99-117385

Published: 2018

Journal Articles

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Blood (2018) 132 (Supplement 1): 959.

DOI: https://doi.org/10.1182/blood-2018-99-119717

Published: 2018

Journal Articles

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Carlos Fernandez de Larrea, MD PhD, David Moreno, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Ignacio Isola, MD, Laura Magnano, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 1610.

DOI: https://doi.org/10.1182/blood-2018-99-115038

Published: 2018

Journal Articles

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

Luis Gerardo Rodríguez-Lobato, MD PhD, Carlos Fernández De Larrea, MD PhD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Joan Bladé, MD PhD, Laura Rosinol, MD PhD

Blood (2018) 132 (Supplement 1): 5573.

DOI: https://doi.org/10.1182/blood-2018-99-112089

Published: 2018

Journal Articles

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Blood (2018) 132 (Supplement 1): 589.

DOI: https://doi.org/10.1182/blood-2018-99-110471

Published: 2018

Journal Articles

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Natalia Tovar, MD PhD, Maria Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2018) 132 (Supplement 1): 3155.

DOI: https://doi.org/10.1182/blood-2018-99-112222

Published: 2018

Journal Articles

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Carlos Fernandez de Larrea, MD PhD, Tania Diaz, PhD, Alfons Navarro, PhD, Ester Lozano, PhD, Mari-Pau Mena, PhD, Ignacio Isola, MD, Mª Teresa Cibeira, MD PhD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 4362.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4362.4362

Published: 2017

Journal Articles

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

Raquel Jiménez, MD, Laura Rosinol, MD PhD, Maria Teresa Cibeira, MD PhD, Carlos Fernández De Larrea, MD PhD, Esther Blade, Natalia Tovar, MD PhD, Joan Bladé, MD PhD

Blood (2017) 130 (Supplement 1): 3140.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3140.3140

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Carlos Fernandez de Larrea, MD PhD, Luis Gerardo Rodríguez-Lobato, MD, Natalia Tovar, MD PhD, Laura Magnano, MD, Ignacio Isola, MD, Laura Rosinol, MD PhD, Joan Bladé, MD PhD, Mª Teresa Cibeira, MD PhD

Blood (2017) 130 (Supplement 1): 5365.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.5365.5365

Published: 2017

NARROW

Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/or Refractory Multiple Myeloma

CAR Density Influences Antitumoral Efficacy of BCMA CAR-T Cells and Correlates with Clinical Outcome

Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Immunoparesis Defined By Heavy/Light Chain Pair Suppression in Smoldering Multiple Myeloma Patients Shows Isotype Specificity

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Smoldering Multiple Myeloma: Usefulness of Serum Heavy/Light Chain Measurements for the Evaluation of Evolving Pattern

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Natural History of Asymptomatic IgM Monoclonal Gammopathies: Impact of the Bone Marrow Aspiration into the Classification and Prognosis

Survival Improvement in the Last 45 Years in Patients with Multiple Myeloma: Real-World Data from a Single Center

CAR T Cell Therapy Targeting G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), a Novel Target for the Immunotherapy of Multiple Myeloma

Mir-485-3p and Mir-654-3p Expression in Bone Marrow Mesenchymal Stromal Cells in Patients with Monoclonal Gammopathies Is Related to the Status of the Disease

Micrornas in Bone Marrow Mesenchymal Stromal Cells Are Differentially Expressed According to Response in Multiple Myeloma

Incidence and Outcome of Soft-Tissue Plasmacytomas in Patients with Multiple Myeloma before and after the Introduction of Novel Drugs

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Bone Marrow Plasma Cell Infiltration in Light Chain Amyloidosis: Impact on Organ Involvement and Outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only